Chester County News and Community Website
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) presented preclinical and translational data on its clinical asset, CT-95, at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The …
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has received FDA approval to move forward with its Virtue Trial, a pivotal clinical study designed to evaluate its next-generation …
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is set to showcase critical new findings on resmetirom, its liver-targeted thyroid hormone receptor (THR)-β agonist, at the European Association for the …
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 Read More
WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly statistically significant and clinically meaningful improvement in …
DESTINY-Breast09 Trial Demonstrates Promising Results for ENHERTU in Combination with Pertuzumab Read More WILMINGTON, DE — High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, significantly improves progression-free survival (PFS) compared to the current 1st-line …
ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer Trial Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the publication of groundbreaking Phase 2 trial results for its medication lorundrostat in the New England Journal of Medicine (NEJM). The …
Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ATI-052, a bispecific …
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial Read More
WAYNE, PA — Cagent Vascular has announced the enrollment of the first patient in its groundbreaking Serranator vs. POBA OCT Study. This innovative clinical trial aims to evaluate the benefits …
Cagent Vascular Launches Landmark Study on Serration Angioplasty Technology Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study evaluating ZYN002, a potential treatment for Fragile X syndrome (FXS). The …
Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORINâ„¢ rapamycin 3.9% anhydrous gel for microcystic lymphatic malformations (microcystic LMs) at the 15th World …
Palvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic Disorder Read More